dr. el-khoueiry on choosing between immunotherapy agents and tkis in hcc
Published 5 years ago • 64 plays • Length 2:32Download video MP4
Download video MP3
Similar videos
-
1:22
dr. el-khoueiry on choosing between lenvatinib and sorafenib in hcc
-
2:27
dr. el-khoueiry on immunotherapy combinations in hcc
-
1:38
dr. el-khoueiry discusses research on biomarkers in hcc
-
1:35
dr. el-khoueiry on evolving role of immunotherapy in hcc
-
1:16
dr. el-khoueiry on the frontline treatment landscape in hcc
-
1:12
dr. el-khoueiry discusses recent combination data in hcc
-
1:42
dr. el-khoueiry on the role of ramucirumab in advanced hcc
-
7:13
immunotherapy in hcc
-
2:18
use of immunotherapy for hcc
-
2:24
emerging i-o combination trials in unresectable hcc
-
59:57
exploring new treatment options in hcc
-
9:52
factors in selecting immunotherapy or tki inhibition
-
9:32
dr. el-khoueiry, usc october researcher of the month
-
0:55
dr. cohen on immunotherapy in head and neck squamous cell carcinoma
-
0:42
dr. kudchadkar on immunotherapy in merkel cell carcinoma
-
1:28
dr. el-khoueiry on the rationale for evaluating nivolumab in advanced hcc
-
1:05
dr. kim on role of frontline immunotherapy in advanced hcc
-
4:34
hepatocellular carcinoma’s future treatment paradigm
-
2:22
dr. khleif on next steps to take with immunotherapy